Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)
China flag China · Delayed Price · Currency is CNY
27.33
-0.87 (-3.09%)
Aug 21, 2026, 3:00 PM CST

SHA:688076 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
783.96913.79571.39749.08399.96591.88
Trading Asset Securities
156.9116208-43.0187.13
Cash & Short-Term Investments
940.861,030779.39749.08442.98679.01
Cash Growth
28.07%32.13%4.05%69.10%-34.76%353.54%
Accounts Receivable
537.8508.32539.21297.26251.29143.37
Other Receivables
7.7274.9963.293.271.191.05
Receivables
545.53583.31602.5300.53252.48144.41
Inventory
899.34859.52584.04377.17323.48250.82
Prepaid Expenses
-0.09----
Other Current Assets
101.5139.6739.667.9833.5329.86
Total Current Assets
2,4872,5122,0061,4951,0521,104
Property, Plant & Equipment
3,0392,9921,8921,405988.47706.55
Long-Term Investments
264.47234.47215.04117.594.5-
Goodwill
156.34156.34156.34156.34156.34160.92
Other Intangible Assets
204.41154.82108.19112.198.1888.57
Long-Term Deferred Tax Assets
131.02128.2184.3746.6528.1316.63
Long-Term Deferred Charges
310.22347.59203.241.0338.7715.66
Other Long-Term Assets
222.75214.69409.4173.8465.4434.46
Total Assets
6,8166,7405,0743,5472,5222,127

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
609.37319.92159.7141.9387.6172.36
Accrued Expenses
46.62179.66149.1286.1448.4943.99
Short-Term Debt
1,0221,0171,044546.02318.7377.27
Current Portion of Long-Term Debt
344276.1117.8940.08--
Current Portion of Leases
-15.39.795.291.473.64
Current Income Taxes Payable
31.96.0619.3511.475.37-
Current Unearned Revenue
42.6948.1761.218.396.8526.17
Other Current Liabilities
29.71300.84191.83134.0182.851.96
Total Current Liabilities
2,1272,1631,753973.34551.32275.4
Long-Term Debt
1,3221,322445.21286.49--
Long-Term Leases
27.4428.8925.7517.18-2.74
Long-Term Unearned Revenue
154.79156.855.9931.4635.3221.74
Long-Term Deferred Tax Liabilities
7.78.278.6110.1610.774.26
Other Long-Term Liabilities
48.3259.18107.4339.31-14
Total Liabilities
3,6863,7392,3961,358597.41318.14

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
316.05316.05219.78213.18213.18213.18
Additional Paid-In Capital
1,7551,7551,5981,3411,3191,318
Retained Earnings
1,049919.08766.56495.37374.95277.82
Comprehensive Income & Other
-4.11-4.3672.17120.233.332.2
Total Common Equity
3,1162,9862,6562,1701,9101,811
Minority Interest
13.6416.221.9519.0414.66-2.61
Shareholders' Equity
3,1293,0022,6782,1891,9251,809
Total Liabilities & Equity
6,8166,7405,0743,5472,5222,127

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
2,7152,6601,642895.07320.1983.65
Net Cash (Debt)
-1,774-1,630-863.06-145.98122.79595.36
Net Cash Growth
-----79.38%-
Net Cash Per Share
-5.61-5.20-2.80-0.490.412.21
Filing Date Shares Outstanding
316.05316.05307.69298.46298.46298.46
Total Common Shares Outstanding
316.05316.05307.69298.46298.46298.46
Working Capital
360.63349.12252.82521.43501.15828.71
Book Value Per Share
9.869.458.637.276.406.07
Tangible Book Value
2,7552,6742,3921,9021,6561,562
Tangible Book Value Per Share
8.728.467.776.375.555.23
Buildings
---504.29476.24376.08
Machinery
-2,4181,6031,123652.13529
Construction In Progress
-692.57339.92185.96180.1134.85